Compare IDEXX Laboratories, Inc. (IDXX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs UiPath Inc — how do they compare? IDEXX Laboratories, Inc. trades at $588.36 (market cap $46.93B), while UiPath Inc trades at $15.67 (market cap $8.08B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.8× UiPath Inc's market cap, and UiPath Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | PATH | |
|---|---|---|
Market Cap | $46.93B | $8.08B |
Sector | Health | Technology |
52-Week High | $766.68 | $19.29 |
52-Week Low | $526.44 | $9.38 |
Enterprise Value | $47.83B | $6.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $586.67, down 0.56% on the day, with strong technical momentum showing bullish moving averages and key resistance at $590. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 8.4% and full-year guidance raised to $14.69-14.94. Revenue growth accelerated to 10% year-over-year, supported by 9% organic growth in companion animal diagnostics. Net income margin expanded to 25.03% with exceptional ROE of 74.21%, though valuation multiples remain elevated at P/E 41.23.
Outlook remains positive with analyst consensus at 56.5% buy ratings, though premium valuation and competitive pressures present risks. The stock's technical setup suggests potential breakout above $590 resistance could target $609-618 levels, while support at $578-570 provides downside protection. Continued execution on international expansion and diagnostic adoption supports growth trajectory.
UiPath (PATH) trades at $15.05, up 7.5% amid an AI stock rally, with technical indicators showing bullish momentum despite an overbought RSI. The company demonstrates strong revenue growth, improving from $892M in 2022 to $1.43B in 2025, with net income turning positive in 2026. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beating estimates. Analyst sentiment remains cautious with a $13.33 consensus target below current price.
PATH offers exposure to enterprise automation growth with improving profitability, but faces execution risks and competitive pressures. The stock trades at premium valuations (P/E 25.08, P/S 4.86) while cash flow trends show improvement from negative $182M in 2025 to projected negative $67M in 2026. Key risks include AI competition and software spending volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
